Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
259 results about "Bone metastasis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Bone metastasis is cancer that starts in one area and then spreads to a bone. Some examples are lung, breast, thyroid, prostate, and kidney cancers.
Ablation treatment of bone metastases
InactiveUS6881214B2Easily toleratedReduce the dependency of the patientDiagnosticsSurgical needlesElectrode placementHigh frequency power
Ablative treatment of metastatic bone tumors and relief of pain associated with metastatic bone tumors is achieved by heat ablation of the bone tumor or tissue near the bone tumor by an ablation probe. In one form the probe is an electrode coupled to a high frequency power supply to provide ablative heating of tissue proximate to an electrode that is placed in or near the bone tumor. Cooling of the electrode by fluid circulation from a cooling apparatus outside the patient's body may be used to enlarge the region of high frequency heating around the electrode. Image guidance of the electrode placement may be monitored by an imaging device. Tracking of the electrode by an image-guided navigator helps in placement of the electrode with respect to the configuration of the bone and bone metastasis. A set of tools accommodates biopsy and various shapes of electrodes according to clinical requirements. Several forms of electrodes, energy delivery and cooling apparatus and methods accommodate the specific objectives.
Owner:COVIDIEN AG
Ablation treatment of bone metastases
InactiveUS20050192564A1Easily toleratedReduce the dependency of the patientDiagnosticsSurgical needlesElectrode placementAbnormal tissue growth
Ablative treatment of metastatic bone tumors and relief of pain associated with metastatic bone tumors is achieved by heat ablation of the bone tumor or tissue near the bone tumor by an ablation probe. In one form the probe is an electrode coupled to a high frequency power supply to provide ablative heating of tissue proximate to an electrode that is placed in or near the bone tumor. Cooling of the electrode by fluid circulation from a cooling apparatus outside the patient's body may be used to enlarge the region of high frequency heating around the electrode. Image guidance of the electrode placement may be monitored by an imaging device. Tracking of the electrode by an image-guided navigator helps in placement of the electrode with respect to the configuration of the bone and bone metastasis. A set of tools accommodates biopsy and various shapes of electrodes according to clinical requirements. Several forms of electrodes, energy delivery and cooling apparatus and methods accommodate the specific objectives.
Owner:COVIDIEN AG
Screening assays and methods of tumor treatment
InactiveUS20060015952A1Growth inhibitionBiological material analysisSkeletal disorderAbnormal tissue growthPrimary tumor
The invention relates generally to the screening of candidate molecules for the treatment of tumor metastasis, and treatment methods using such molecules. Thus, the invention includes a method of screening comprising the steps of: (1) administering a plurality of test substances to a non-human syngeneic immunocompetent animal model bearing at least one soft tissue or bone metastasis, in the presence or absence of a primary tumor; (2) determining the effects of the test substances on the soft tissue or bone metastasis and growth of the primary tumor, if present; and (3) identifying a test substance that inhibits the growth of a soft tissue or bone metastasis, without adverse effect on the status of the primary tumor, if present.
Owner:GENENTECH INC
Method for the prognosis and treatment of cancer metastasis
InactiveUS20160032400A1Increased riskOrganic active ingredientsLibrary screeningPrimary NeoplasmCancer metastasis
The present invention relates to a method for the prognosis of bone metastasis in cancer which comprises using a probe to determine if a gene of interest is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise using a probe to determine the expression level of a gene of interest, or the amplification or translocation of a gene of interest. The invention also relates to a method for predicting early bone metastasis in a subject suffering cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of cancer metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering cancer and for classifying a subject from cancer into a cohort.
Owner:INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS +1
SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV
SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-alpha MODULATORS
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV
Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss
This invention relates to pyrimidine compounds of formula (I), formula (I′), and formula (I″):and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R1, R2, R3, R4, R5, U, V, W, X, Y, Z, and n are defined herein. This invention also relates to compositions comprising these compounds and methods for using them. The compounds and compositions of this invention are useful to treat or prevent disorders associated with excessive bone loss, including, without limitation periodontal disease, non-malignant bone disorders (such as osteoporosis, Pagers-disease of bone, osteogenesis imperfecta, fibrous dysplasia, and primary hyperparathyroidism) estrogen deficiency, inflammatory bone loss, bone malignancy, arthritis, osteopetrosis, and certain cancer-related disorders (such as hypercalcemia of malignancy (HCM), osteolytic bone lesions of multiple myeloma and osteolytic bone metastases of breast cancer and other metastatic cancers).
Owner:SYNTA PHARMA CORP
Endothelin antagonists
InactiveUS7208517B1Suppression problemAvoid problemsBiocideAnimal repellantsLymphatic SpreadMedicine
A compound of the formula (I):or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, a method of antagonizing endothelin, methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist.
Owner:ABBVIE INC
Substituted phenoxy n-alkylated thiazolidinediones as estrogen related receptor-alpha modulators
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV
Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
InactiveUS20140105918A1Prevents and reduces bone metastasisPrevent and reduce riskOrganic active ingredientsSugar derivativesPrimary tumorLymphatic Spread
The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
Owner:INBIOMOTION
Co-administration of steroids and zoledronic acid to prevent and treat side effects from zoledronic acid infusion
ActiveUS20110263537A1Prevent and treat side effectBiocideOrganic active ingredientsPaget DiseaseSide effect
Zoledronic Acid is used for treatment of hypercalcemia of malignancy, for the treatment of bone metastasis associated with malignancies such as prostate and breast cancer, for the prevention of and treatment of osteoporosis and for the treatment of Paget's disease. Administration of Zoledronic Acid is complicated by what is described as “post-dosing syndrome” (PDS) and osteonecrosis of the jaw (ONJ). Inflammation may be the cause of these side effects, which could be decreased by the co-administration of steroids. This application is a method of use patent for the co-administration of steroids (oral, IV, IM, rectal, or by inhalation) with Zoledronic Acid and a composition of matter patent for mixing Methyl Prednisolone with Zoledronic Acid for infusion.
Owner:DESAI KETAN
System for detecting bone cancer metastases
ActiveUS20130094704A1Mitigate or eliminate one orReduce needImage enhancementImage analysisLymphatic SpreadFeature extraction
The invention relates to a detection system for automatic detection of bone cancer metastases from a set of isotope bone scan images of a patients skeleton, the system comprising a shape identifier unit, a hotspot detection unit, a hotspot feature extraction unit, a first artificial neural network unit, a patient feature extraction unit, and a second artificial neural network unit.
Owner:EXINI DIAGNOSTICS
System for detecting bone cancer metastases
ActiveUS8855387B2Mitigate or eliminate one orReduce needImage enhancementImage analysisFeature extractionMedicine
The invention relates to a detection system for automatic detection of bone cancer metastases from a set of isotope bone scan images of a patients skeleton, the system comprising a shape identifier unit, a hotspot detection unit, a hotspot feature extraction unit, a first artificial neural network unit, a patient feature extraction unit, and a second artificial neural network unit.
Owner:EXINI DIAGNOSTICS
Method for the Diagnosis, Prognosis and Treatment of Breast Cancer Metastasis
ActiveUS20140057796A1Positive diagnosisGreat tendency to develop metastasisSugar derivativesMicrobiological testing/measurementBreast cancer metastasisPrimary tumor
The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER− breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER− breast cancer metastasis.
Owner:INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS +1
Method of Treating Cancer
InactiveUS20160220554A1Relieve painImprove survivalOrganic chemistrySkeletal disorderOsteoblastDual inhibitor
Owner:EXELIXIS INC
Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
ActiveUS20150362495A1Prevent and reduce riskReduce and preventBiocideLibrary screeningPrimary tumorLymphatic Spread
Owner:INBIOMOTION
Method of Treating Cancer
This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.
Owner:EXELIXIS INC
Method of Treating Cancer
InactiveUS20140066444A1Relieve painImprove survivalAntineoplastic agentsHeterocyclic compound active ingredientsOsteoblastDual inhibitor
This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.
Owner:EXELIXIS INC
Method for the diagnosis, prognosis and treatment of lung cancer metastasis
ActiveUS20150152506A1Valuable informationOrganic active ingredientsLibrary screeningPrimary tumorLymphatic Spread
The present invention relates to a method for the diagnosis or the prognosis of metastasis in lung cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in lung cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the lung cancer.
Owner:INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS +1
Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
The present invention relates to a method for the prognosis of bone metastasis in renal cell carcinoma which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering renal cell carcinoma. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of renal cell carcinoma metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering renal cell carcinoma and for classifying a subject from renal cell carcinoma into a cohort.
Owner:INBIOMOTION
Method of Treating Cancer
InactiveUS20140323522A1Improve survivalRelieve painBiocideOrganic chemistryDual inhibitorCastration resistant
This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and bone metastases, with a dual inhibitor of MET and VEGF.
Owner:EXELIXIS INC
Method for the Prognosis and Treatment of Cancer Metastasis
InactiveUS20170101683A1Prevents and reduces bone metastasisPrevent and reduce riskMicrobiological testing/measurementImmunoglobulins against cell receptors/antigens/surface-determinantsBreast cancer metastasisMedicine
The present invention relates to a method for the prognosis of bone metastasis in HER2+ breast cancer, which comprises determining if the MAF gene is amplified in a primary tumor sample. Likewise, the present invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the MAF gene expression level, amplification or translocation. The present invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The present invention also relates to a c-Maf inhibitor as therapeutic agent for use in the treatment of HER2+ breast cancer metastasis. The present invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the present invention relates to a method for typing of a subject suffering breast cancer and for classifying a subject from breast cancer into a cohort.
Owner:FUNDACIO INST DE RECERCA BIOMEDICA (IRB BARCELONA) +1
Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment or urogenital cancer and its metastasis
InactiveUS20090011047A1Telomeres shortenImprove the quality of lifeBiocideAntipyreticDiseaseAdjuvant
The present application relates to pharmaceutical compositions and methods for treatment of urogenital diseases and bone metastasis in a human, which pharmaceutical composition contains an effective amount of arsenous acid alkaline or earth alkaline metal salt and / or a pharmaceutically acceptable adjuvant. According to the present invention, the alkaline arsenous acid metal salt is sodium meta-arsenita (AsO2Na) or potassium meta-arsenite (AsO2K). The effective amount of arsenous acid alkaline or earth alkaline metal salt is 0.0001-1500 mg / kg, preferably 1-1000 mg / kg, more preferably 1-150 mg / kg, and most preferably 50-100 mg / kg of body weight / day. The administration form of the pharmaceutical compositions of the invention is preferably oral, such as a tablet, capsule, powder and / or solution with a pharmaceutically acceptable carrier, diluent or excipient.
Owner:KOMINOX
Formulation and method for the prevention and treatment of bone metastases or other bone diseases
InactiveUS20140363413A1Limiting renal eliminationImprove bioavailabilityBiocideOrganic active ingredientsChemical treatmentRed blood cell
Owner:ERYTECH PHARMA
Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
InactiveCN103391773AOrganic chemistryAntipyreticDual inhibitorCastration-Resistant Prostate Carcinoma
Owner:EXELIXIS INC
Method for the Diagnosis, Prognosis and Treatment of Prostate Cancer Metastasis
ActiveUS20170121777A1Great tendencyMicrobiological testing/measurementDisease diagnosisPrimary tumorOncology
The present invention relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
Owner:INBIOMOTION
Method of treating cancer
ActiveUS9861624B2Relieve painImprove survivalSkeletal disorderUrinary disorderDual inhibitorOncology
This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteolytic bone metastases, with a dual inhibitor of MET and VEGF.
Owner:EXELIXIS INC
Method for the prognosis and treatment of cancer metastasis
ActiveUS20170370935A1Microbiological testing/measurementBiological material analysisBreast cancer metastasisBreast cancer classification
Owner:INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS +1
An osteoblast targeted vector constructed based on a polypeptide and preparation and applications thereof
InactiveCN106039316ALittle side effectsImprove targetingPowder deliverySkeletal disorderSide effectMass ratio
The invention relates to an osteoblast targeted vector constructed based on a polypeptide. The targeted vector comprises a target head and a support. The target head is the polypeptide. The grafting mass ratio of the target head is 5-10%, and the mole grafting ratio is 2-6%. The targeted vector is prepared by subjecting the polypeptide and a vector to carboxylic acid covalent linking through polyethylene glycol, and is used for filling medicines treating bone fractures, osteoporosis, osteoarthritis, rheumatoid arthritis or tumor bone metastasis. Compared with the prior art, the targeted vector has osteoblast targeting performance, high bone tissue affinity and efficient medicine delivery capability, and is capable of enhancing osteogenesis effects, reducing medicine using amounts, and reducing cell toxicity and side effects. The targeted vector provides an important medicine delivery tool for future osteoporosis treatment.
Owner:TONGJI UNIV
Anti human RANKL monoclonal antibodies developed by PAE technology and uses thereof
InactiveCN102741286ADifferent mechanism of actionGood curative effectSkeletal disorderImmunoglobulins against cell receptors/antigens/surface-determinantsOsteopetrosisAmino acid
The invention discloses antibodies that bind high specificity to human RANKL (Receptor Activator for Nuclear Factor kappa B Ligand), wherein, the antibodies are used for the treatment of bone erosion caused by astogeny, hormonotherapy, postmenopausal osteoporosis, bone metastasis, and inflammation. The invention also discloses DNA sequences and supposed amino acid sequences of the antibodies.
Owner:刘庆法
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com